Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended
Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or
metastatic squamous cell carcinoma of the head and neck who have failed platinum or a
platinum containing regimen.
In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab
versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose
identified in PIIa.